Subscribe
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Archive

Arexvy recommended for adults aged 50-59 at increased risk for severe respiratory syncytial virus disease by US Advisory Committee on Immunization Practices – GSK

Written by | 28 Jul 2025

GSK plc announced that the Advisory Committee on Immunization Practices (ACIP) voted in favour of recommending the use of RSV vaccines including GSK’s Arexvy (Respiratory Syncytial Virus Vaccine,… read more.

Nucala (mepolizumab) approved by US FDA for use in adults with chronic obstructive pulmonary disease – GSK

Written by | 18 Jul 2025

GSK plc announced that the FDA has approved Nucala (mepolizumab) as an add-on maintenance treatment for adult patients with inadequately controlled COPD and an eosinophilic phenotype. FDA’s approval… read more.

Blenrep (belantamab mafodotin) combinations approved by UK MHRA in relapsed/refractory multiple myeloma – GSK

Written by | 7 Jul 2025

GSK plc announced the authorisation of Blenrep by the Medicines and Healthcare products Regulatory Agency (MHRA). In the UK, Blenrep is approved for the treatment of adults with… read more.

GSK to present 43 Abstracts at ATS 2025, highlighting advances in asthma, COPD and respiratory innovation

Written by | 14 May 2025

GSK plc announced data from across its respiratory portfolio will be presented in 43 abstracts, including four late-breaking submissions, at the 2025 American Thoracic Society (ATS) International Congress in… read more.

Blenrep (belantamab mafodotin) combinations approved by UK MHRA in relapsed/refractory multiple myeloma – GSK

Written by | 10 May 2025

GSK plc announced the authorisation of Blenrep by the Medicines and Healthcare products Regulatory Agency (MHRA). In the UK, Blenrep is approved for the treatment of adults with… read more.

GSK’s 5-in-1 meningococcal vaccine Penmenvy receives positive recommendation from US Advisory Committee on Immunization Practices

Written by | 30 Apr 2025

GSK plc announced that the US Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP) has voted to recommend use of Penmenvy (Meningococcal Groups… read more.

FDA approves Blujepa (gepotidacin) for treatment of uncomplicated urinary tract infections in female adults and paediatric patients 12 years of age and older – GSK

Written by | 1 Apr 2025

GSK plc announced that the FDA has approved Blujepa (gepotidacin) for the treatment of female adults (≥40 kg) and paediatric patients (≥12 years, ≥40 kg) with uncomplicated urinary… read more.

Blenrep (belantamab mafodotin) combination accepted for priority review in China in relapsed/refractory multiple myeloma – GSK

Written by | 18 Mar 2025

GSK plc announced that the National Medical Products Administration (NMPA) of China has accepted for review a new drug application (NDA) for Blenrep (belantamab mafodotin) in combination with… read more.

ViiV Healthcare to present latest advances in HIV treatment and prevention at CROI 2025

Written by | 16 Mar 2025

GSK plc announced that ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, will be presenting abstracts from its innovative HIV… read more.

Penmenvy, meningococcal vaccine, approved by FDA to help protect against MenABCWY – GSK

Written by | 24 Feb 2025

GSK plc announced that the FDA has approved Penmenvy (Meningococcal Groups A, B, C, W, and Y Vaccine) for use in individuals aged 10 through 25 years. The… read more.

Nucala (mepolizumab) approved in China for treatment of adults with chronic rhinosinusitis with nasal polyps – GSK

Written by | 16 Feb 2025

GSK plc announced that the China National Medical Products Administration has approved Nucala (mepolizumab), a monoclonal antibody that targets interleukin-5 (IL-5), as an add-on therapy with intranasal corticosteroids… read more.

Shingrix new prefilled syringe presentation accepted for review by European Medicines Agency – GSK

Written by | 1 Feb 2025

GSK plc announced that the EMA has accepted for review the regulatory application of a prefilled syringe presentation of Shingrix (GSK’s Recombinant Zoster Vaccine or RZV) for the… read more.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.

Subscribe

You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.